Uplizna
What Uplizna is used for
Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Uplizna
- Active substance
- inebilizumab
- Disease area
- Neuromyelitis Optica
- Medicine group
- Immunosuppressants
- ATC code
- L04AA
- Marketing authorisation holder
- Amgen Europe B.V.
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Uplizna
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Uplizna used for?
Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1).
What is the active substance in Uplizna?
Uplizna contains inebilizumab.
Who makes Uplizna?
The EU marketing authorisation holder is Amgen Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU